Category Archives: Cancer

Eric Lefkofsky Entrepreneur and Philanthropist Focused on Cancer Treatment Efficiency

Cancer is one of the most prevalent diagnoses at nearly 40 percent. Information from the National Cancer Institute shows about 14.5 million Americans were living with cancer in 2014. This percentage is expected to rise with approximately 19 million people living with cancer in just ten years later by 2024. There are companies that are trying to reduce the numbers by helping change the prognosis like Tempus. This company was co-founded by Eric Lefkofsky to make it possible for data-enabled precision medicine.

Before Tempus there were problems with electronic health records in the healthcare industry and the firm has made it a goal to transform the way cancer care is delivered by developing a platform that analyzes the patient’s clinical and molecular data. The company developed analytics software, but it was the actual data that was a problem, so Tempus developed software that includes a natural language processing and optical character recognition capabilities. Then the physician’s notes could be transformed to data. The molecular data gathered can be processed in human genome sequencing. This can be essential in cancer patient treatment since research focuses on the molecular and cellular levels. The analysis software by Tempus can make fighting cancer and other diseases more effective. It also gives researchers hope that they can unlock the mysteries that can make advances in treating diseases like cancer.

Eric Lefkofsky entrepreneur and philanthropist along with the co-founder and CEO of Tempus technology company as well as the founder of Groupon. Mr. Lefkofsky is the co-founder of Echo Global Logistics, InterWorkings, Mediaocean, Uptake and Chicago’s venture capital firm Lightbank.

Mr. Lefkofsky attended the University of Michigan graduating with honors in 1991 and attended the University of Michigan Law School earning a Juris Doctor in 1993. In 1999 Lefkofsky and Brian Keywell started his first company. Mr. Lefkofsk joined Halo becoming the chief operating officer. By 2001 he co-founded InnerWorkings that by 2006 was listed on Nasdaq. Mr. Lefkofsky has taught at DePaul University Kellstadt Graduate School of Business, North Western University Kellogg School of Management and currently is an adjunct professor at University of Chicago Booth School of Business. He serves on the board of directors at Children’s Memorial Hospital, the Art Institute of Chicago and is Chairman of the Board of Trustees of Chicago Steppenwolf Theater Company.

To know more visit @:

Dr. Mikhail Blagosklonny Advancing in his Research on Oncology and Biogerontology

Oncology and anti-aging are two of the most discussed topics in the world of medicine. Dr. Mikhail Blagosklonny has spent his life and career dedicated to both of those fields of Oncology and Biogerontology.Dr. Mikhail Blagosklonny is of Russian origins. He was born in Russia, and he also achieved his higher education in St. Petersburg as he attended the First Pavlov State University. His alma mater is one of the esteemed universities in the city. Dr. Mikhail Blagosklonny earned both a Ph. D and an M. D. He majored in internal medicine and after that in cardiology and experimental medicine.Upon his graduation, Dr. Mikhail Blagosklonny moved to the United States of America. He started living in New York City where he took up a post at the New York Medical College. Dr. Mikhail Blagosklonny tough medicine for a few years but eventually he decided to do a transition and start doing medical research instead.

In order to accommodate the new path of his career, Dr. Mikhail Blagosklonny began working at the Ordway Research Institution during the years between 2002 and 2009. His new work place was located in Albany, New York. Dr. Mikhail Blagosklonny was holding the post of senior scientist. Over the course of his career at the Ordway Research Institution, Dr. Mikhail Blagosklonny was able to advance significantly in his research in oncology and biogerontology. However, there was only so much the institution could offer. Dr. Mikhail Blagosklonny left the Ordway Research Institution, and in 2009 he continued his studies at the Roswell Park Cancer Institute. While the Ordway Research Institute had a lot to offer Dr. Mikhail Blagosklonny in the beginning stages of his career, the Roswell Park Cancer Institute had a more streamlined and a lot fuller range of possibilities for scientists and researchers. Dr. Mikhail Blagosklonny is still donged his research at the Roswell Park.

So far, Dr. Mikhail Blagosklonny has made many a contribution to the fight against cancer. In terms of biogerontology, Dr. Mikhail Blagosklonny has become a supporter of the notion that the drug Rapamycin could potentially slow down aging. Rapamycin is a drug which is often used in therapy treatments against cancer. While the use of Rapamycin against anti-aging is still debatable, the scientific community is analyzing the idea, and there is some research under way as well.Dr. Mikhail Blagosklonny is eloquent in writing as well. He has been documenting his research for many years, and he has also written papers and articles on many topics in the fields of biogerontology and oncology as well. Dr. Mikhail Blagosklonny started working as an editor in chief a handful of years ago when the online medical journal of Oncotarget launched. Not only that, but Dr. Mikhail Blagosklonny has been doing peer reviews as an editor for other j=journals such as Cell Cycle and Aging. Over the course of his career, there have been more than a hundred original publications with the name of Dr. Mikhail Blagosklonny under it as he has become a prolific editorial writer as well.

Eric Lefkofsky works to make sense of human genome

In the mid-’90s, a revolution in cancer therapy swept through the field like wildfire. The so called targeted therapies began coming on scene. These drugs and treatments regimens promised to all but eliminate the horrible side effects of cancer treatments like chemotherapy. Since then, they have made real progress in allowing oncologists to specifically attack malignant cells, leaving healthy cells alone. This has led to the development of many new drugs, with the promise to radically increase the survivability of certain types of cancers.

Today, a new revolution is taking place in cancer treatment. Like the targeted therapy revolution, this new wave of innovation promises to dramatically increase survivability, while all but eliminating the collateral damage that so often accrues to those undergoing cancer treatment. This new revolution in cancer therapy involves the customization of treatment regimes, using mind-blowingly sophisticated means of automated, real-time analysis to tailor drugs and treatment course directly to individual patients’ needs.

One man, Eric Lefkofsky, is at the center of this new revolution in cancer treatment. Through his company, the recent startup Tempus, he seeks to take the vast troves of unparsed data, which are quickly expanding, due to the ability of cheap human genome sequencing, and connect all of the relevant dots.

Many people don’t realize how blunt even the most cutting-edge cancer treatments often are today. Within cancer types, there is little distinction between patient cohorts. A patient who is diagnosed with stage IV pancreatic cancer is likely to receive essentially the same treatment as everyone else with the same diagnosis. But Tempus is about to change all of that.

Using high-tech machine learning algorithms, Tempus is taking vast amounts of genomic, research and medical record data and combining them to give oncologists and more complete and better-informed clinical picture of not just the patient’s disease but the treatment regimens that are most likely to maximize that patient’s survival. Through the use of this system, Lefkofsky believes that, someday soon, it will be possible to devise a totally custom treatment program, tailored to each individual patient. This could double or even triple average survival times in the next five to ten years.

To know more visit @: